MICROBIO Business Summary

Microbio Co., Ltd. (4128.TWO) operates a diversified biotechnology business model centered on three primary pillars: the commercialization of organic health products, the development of innovative biopharmaceuticals, and strategic venture investments within the life sciences sector. Revenue is primarily generated through the sale of proprietary fermented soy-based health supplements and organic foods under its established retail brands, supplemented by milestone payments and licensing fees from its R&D pipeline, which focuses on oncology, immunology, and metabolic diseases. The company’s business segments are categorized into New Drug Development, Health Products, and Investment Holdings. Within the Taiwanese market, Microbio competes directly with OBI Pharma, TaiMed Biologics, and PharmaEssentia. It distinguishes itself as a vertically integrated incubator and holding company that bridges the gap between traditional nutritional science and advanced biologics, maintaining a significant strategic influence through its ownership stakes in high-growth affiliates like Oneness Biotech. The company is led by Founder and Chairman Lu-Chi (K.M. Lu), a pivotal figure in the Asia-Pacific biotechnology landscape who also serves as the Chairman of Oneness Biotech and is widely credited with architecting one of Taiwan's most successful biotech ecosystems. The leadership team includes seasoned executives with backgrounds from Academia Sinica and international pharmaceutical firms, ensuring a rigorous scientific approach to their proprietary fermentation technologies and monoclonal antibody platforms. The board of directors and capital structure are notably supported by the Diamond BioFund, Taiwan’s largest private biotech venture capital fund, which provides significant financial backing and strategic oversight. This leadership configuration combines Lu’s expertise in capital markets and industrial scaling with a specialized technical bench focused on transforming traditional medicinal concepts into globally competitive clinical assets.